Lancet: Higher mortality rate from new coronary pneumonia in cancer patients

Recently, researchers examined the COVID-19 burden in cancer patients and identified potential prognostic factors for mortality and serious diseasesresearchers collected data on new coronary pneumonia infections in patients 18 years of age and older with active or past malignancies, from the United States, Canada and Spain, diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and collected data on baseline clinical conditions, drugs, cancer diagnosis and treatment, and coVID-19 disease coursesThe main endpoint of the study was the cause-of-all mortality rate within 30 days of COVID-19 diagnosis928 patients participated in the study, with an average age of 66 years, 279 (30%) aged 75 years or older, and 468 (50%) of the patients were maleThe most common malignant tumors were breast cancer (191 cases, or 21 per cent) and prostate cancer (152 cases, or 16 per cent)366 patients (39%) received active anti-tumor therapy and 396 (43%) had active (measurable) cancerIn the analysis (7 May 2020), 121 patients (13%) diedIn the logical regression analysis, the independent factors associated with the increase in the adjusted 30-day mortality rate were: age increase (1.84 for every 10 years of age increase), male (1.63), smoking status (previous smoker vs never smokers ratio: 1.60), total disease Number (2 vs None: 4.50), ECOG score 2 or higher (2 vs0 or 1:3.89), active cancer (progressive vs remission: 5.20, azithromycin plus hydroxychloroquine treatment (vs not using two treatments: 2.93)People living in Canada (0.24) or the Midwest (0.50) had a lower 30-day mortality rate for 30 days than those living in the Northeast United Statesstudies found that the 30-day mortality rate of new coronary pneumonia in tumor patients was higher, and the general risk factors and specific risk factors in tumor patients played a greater role